Targeting PGRN might be an interesting approach in cell-based assays; its feasibility in patients, however, depends on the precision in targeting cancers and the temporal availability, as systematic downregulation could lead to severe neurological effects and increased inflammation2,6,7. The gene discussed is GRN; the disease is cancer.